Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery
Rhea-AI Summary
Rani Therapeutics (NASDAQ: RANI) announced it will present preclinical data for its RaniPill® capsule at ENDO 2025 in San Francisco. The presentation will showcase research demonstrating bioequivalence between oral delivery of a bispecific GLP-1/GLP-2 receptor agonist (PG-102) using their robotic pill (RT-114) and traditional subcutaneous injection in canines.
The poster presentation, titled "Oral Delivery of a Bispecific GLP-1/GLP-2 Receptor Agonist (PG-102) via a Robotic Pill (RT-114)," will be presented by Dr. Anvesh Dasari on July 14, 2025, from 12:00 PM to 1:30 PM PT, as part of the session on adipose tissue, appetite, and obesity therapeutic advances.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, RANI gained 8.45%, reflecting a notable positive market reaction. Argus tracked a trough of -19.9% from its starting point during tracking. Our momentum scanner triggered 42 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $2M to the company's valuation, bringing the market cap to $31M at that time. Trading volume was very high at 3.4x the daily average, suggesting strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
SAN JOSE, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present preclinical data on the RaniPill® capsule at the Endocrine Society’s Annual Meeting (ENDO 2025) taking place July 12-15 in San Francisco, CA.
Details of the presentations are as follows:
Abstract Title: Oral Delivery of a Bispecific GLP-1/GLP-2 Receptor Agonist (PG-102) via a Robotic Pill (RT-114) Achieves Bioequivalence to Subcutaneous Injection in Canines
Session Type: Poster Presentation
Session Title: Adipose Tissue, Appetite, and Obesity: From Breakthroughs to Real-World Challenges: Navigating Weight Loss, Regain, and Therapeutic Advances II
Session Date & Time: July 14, 2025 from 12:00 PM to 1:30 PM PT
Poster Number: MON-691
Presenting Author: Anvesh Dasari, PhD
The abstract presented at ENDO 2025 is available on the Endocrine Society website.
About Rani Therapeutics
Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill® capsule, which is a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill® capsule technology. For more information, visit ranitherapeutics.com.
Investor Contact:
investors@ranitherapeutics.com
Media Contact:
FAQ
When is Rani Therapeutics (RANI) presenting at ENDO 2025?
What will Rani Therapeutics (RANI) present at ENDO 2025?
Who is presenting the Rani Therapeutics (RANI) research at ENDO 2025?
What is the significance of Rani Therapeutics' (RANI) presentation at ENDO 2025?
